3
1 Introduction
Craniospinal irradiation (CSI) is a curative treatment for several pediatric central nervous system
malignancies. The CSI target volume includes the entire brain and thecal sac as the clinical target volume
to minimize the risk of tumor dissemination throughout the neuroaxis [1]. Conventional photon CSI
treatment may induce various short- and long-term side effects, including odynophagia, anorexia, bone
marrow suppression causing lymphopenia, and secondary malignant neoplasms [2-5] in these young
patients with very favorable prognoses. Clinical evidence also has shown that growing children can further
develop spinal lordosis, kyphosis, or scoliosis when growth plates are asymmetrically irradiated [6-8].
Consequently, pediatric radiation oncologists have historically recommended treating vertebral bodies and
growth plates wholistically for growing children [9]. Even with this practice, Paulino et al. [10] reported
that 16.7% and 54.5% of patients developed scoliosis 15 years after their vertebral ossification centers
received CSI doses of 18 - 24 Gy and 34.2 - 40 Gy, respectively. Thus, a treatment technique with conformal
dose delivery and avoidance of the vertebral bodies is desired for CSI in children to reduce toxicity and
improve quality of life.
Intensity modulated proton therapy [11] is an attractive technique for the treatment of pediatric CNS
malignancies due to its superior dose conformality and reduced integral dose to surrounding healthy tissues.
Clinical evidence has shown that proton CSI can reduce radiation toxicity and achieve equivalent long-term
disease control relative to photon therapy [12-15]. Unlike photon beams, the integral depth dose curve of
proton beams exhibits a distal peak near the end of the proton range (Bragg peak) that enables dose
deposition without significant exit dose. Proton CSI has the potential to leverage this physical feature to
treat the entire thecal sac while sparing the spinal growth plate. However, current proton therapy treatment
planning usually includes a margin of 3.5% reserved for proton range uncertainty [16-18]. Such uncertainty
requires the inclusion of parts of the vertebral bodies during treatment planning to ensure that the target
volume receives adequate dose coverage, and the sparing of growth plates can be compromised.
Given this uncertainty in proton therapy, a method of quantifying the in vivo proton damage during
treatments would be valuable to verify the accuracy of treatments and to facilitate adaptive re-planning, if
necessary, when using a steep dose gradient for vertebral body sparing (VBS). After proton CSI, radiation-
induced fatty marrow infiltration can be observed in the spine following treatment using magnetic
resonance imaging (MRI) [19, 20]. Replacement of hematopoietic marrow provides physiologic evidence
to retrospectively investigate the potential in vivo proton range uncertainty [21, 22]. However, there remains
a paucity of data from which to deduce when marrow conversion happens and how to use this information
to protect vertebral growth plates.
Although fatty marrow replacement has been detected at the end of treatment [23, 24], whether fatty marrow
may be observed on MR images between earlier treatment fractions in children remains unknown. This
study aims to perform MRI at specified intervals during proton VBS CSI to detect how early radiographic
marrow changes become evident and to evaluate whether the planned radiation dose deposition in bone can
be correlated to proportional proton damage within vertebral marrow. These findings may potentially be
used to support real-time medical decision-making, for instance to determine if growth plates are
sufficiently spared or replanning is necessary to reduce excessively conservative proton range margins.
Quantification of uncertainty will be considered to demonstrate the reliability, applicability, and feasibility
of the proposed method for CSI intensity modulated proton therapy with vertebral body sparing.